Research overview
GHRP-2: what the research shows
What is GHRP-2?
GHRP-2, also known by the international nonproprietary name pralmorelin and the development code KP-102, is a synthetic hexapeptide amide: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 [1]. It belongs to the growth hormone-releasing peptide (GHRP) family, small synthetic peptides that stimulate growth hormone (GH) release from the pituitary. Synthetic GH secretagogues were already in use as research tools when their receptor was cloned in 1996, and the cloning team noted that they appeared to mimic a then-undiscovered hormone [4].
A 2004 pharmacology paper characterized KP-102 as a potent synthetic GH secretagogue and reported that its GH-releasing activity in conscious rats was greater than that of exogenous GHRH, and less sensitive to suppression by endogenous somatostatin [2]. In a 1998 swine comparison, GHRP-2 showed higher potency but lower maximal efficacy for GH release than GHRP-6 and ipamorelin, and, unlike ipamorelin, it increased ACTH and cortisol [3].
GHRP-2 is unusual among research peptides in having a long record of human pharmacology, largely through its use as a pituitary stimulation test in Japanese clinical endocrinology research (see the human evidence section).
| Sequence | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (2-Nal = 3-(2-naphthyl)alanine) |
|---|---|
| Length | 6 residues (hexapeptide amide) |
| Molecular formula | C45H55N9O6 |
| Molecular weight | 818.0 g/mol |
| CAS number | 158861-67-7 |
| PubChem CID | 6918245 |
| Other names | Pralmorelin, KP-102, GHRP Kaken 100 (PubChem synonyms) |
Mechanisms studied
The ghrelin receptor (GHS-R1a)
GH secretagogues act through a G protein-coupled receptor cloned in 1996 from pituitary and hypothalamus [4], later named the ghrelin receptor after its endogenous ligand [5]. Because the receptor is expressed at both sites, a recurring question is how much of GHRP-2's effect is direct on the pituitary and how much runs through hypothalamic GHRH.
Pituitary and hypothalamic sites of action
The 2004 KP-102 study found that GH release was completely absent in hypophysectomized rats, present but reduced in rats with lesions of the median eminence, and directly stimulated in cultured rat anterior pituitary cells, although with lower potency than GHRH in vitro. The authors concluded that endogenous GHRH input was needed for the full response [2]. Consistent with this, long-term GHRP-2 exposure in GHRH knockout mice failed to stimulate somatotroph proliferation, GH secretion, or longitudinal growth [6].
Somatotroph electrophysiology
In primary cultured ovine somatotropes, GHRP-2 reversibly reduced the inward-rectifying potassium (Kir) current. This reduction was abolished by protein kinase A inhibitors but not by protein kinase C blockers, and the authors proposed that Kir inhibition through the PKA-cAMP pathway contributes to GHRP-2-induced depolarization and GH release [7].
ACTH release
GHRP-2 is not selective for GH. In mouse anterior pituitary cells, it directly stimulated ACTH secretion and synthesis and increased intracellular cyclic AMP; ACTH release depended on both PKA and PKC pathways, while ACTH synthesis depended on PKA only [8].
Binding to CD36
Some cardiovascular actions of GHRP-family peptides appear to involve a second binding site. Using a labelled derivative of hexarelin, a related GHRP, researchers identified the scavenger receptor CD36 in rat cardiac membranes as a binding protein that mediated coronary effects in perfused hearts [9]. A later study noted that GHRP-2 also binds CD36 [10].
Areas of research
Isolated heart models
In isolated rat hearts subjected to 30 minutes of ischemia followed by reperfusion, KP-102 present in the perfusate was associated with lower end-diastolic pressure and better recovery of developed pressure during reperfusion than in controls. Because isolated hearts have no pituitary input, the authors concluded that the effect was independent of GH secretion [11].
Vascular oxidative stress
A 2009 study in ApoE-deficient mice, a standard atherosclerosis model, reported that GHRP-2 decreased aortic superoxide production and the expression of several inflammatory mediators, and in cultured aortic smooth muscle cells prevented oxidized-LDL-induced peroxide generation and apoptosis. It did not, however, reduce atherosclerotic plaque area [10], a useful reminder that antioxidant signaling in a model does not necessarily change the disease endpoint.
Inflammation models
In a rat model of lipopolysaccharide-induced acute lung injury, GHRP-2 given before the inflammatory challenge was associated with reduced lung edema, neutrophil infiltration, and pro-inflammatory cytokines, along with suppressed NF-kappaB activation in lung tissue [12].
Analytical and anti-doping chemistry
Because GHRP-2 is a prohibited GH releasing factor, doping-control laboratories have developed urine assays for it and its metabolites [13]. GHRP-2 has also been identified in tablets sold as an over-the-counter nutritional supplement [14], illustrating why researchers should rely on independently tested, lot-matched material.
State of the human evidence
GHRP-2 has more human pharmacology data than most compounds in this category, almost all of it diagnostic or mechanistic:
- Pituitary function testing. Japanese clinical studies have evaluated a GHRP-2 stimulation test for assessing pituitary GH reserve in adults [15], and the ACTH response measured during the same test [16].
- Mechanism in people. A 2001 study in individuals with isolated GH deficiency caused by a homozygous GHRH receptor mutation found that GHRP-2 still produced a small GH response, far smaller than in controls, which the authors took as evidence of a GHRH-independent action on somatotroph cells [17].
These are diagnostic and physiological studies, not efficacy trials, and they do not establish safety for any other use. A 2026 narrative review of GH-axis peptides used outside medical supervision described adverse effects reported across GH-axis peptides, including prolactin and cortisol elevations and dysglycaemia [18]. FDA has noted reports of serious adverse events in people who received GHRP-2, while stating that causality has not been established [19].
Regulatory status
- Not FDA approved. A search of Drugs@FDA on October 12, 2026 returned no approved drug product containing GHRP-2 or pralmorelin [20].
- Compounding. FDA's list of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) places GHRP-2 in category 2 under the 503B interim policy for certain routes of administration, added September 29, 2023. FDA cites a potential risk of immunogenicity, the complexity of characterizing a peptide with an unnatural amino acid, and reports of serious adverse events [19].
- Sport. The World Anti-Doping Agency 2026 Prohibited List names GHRP-2 (pralmorelin) under S2.2.4, among GH-releasing peptides, within class S2, which is prohibited at all times [21].
Status checked October 12, 2026. Rejuvatide supplies GHRP-2 strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.
Testing and quality
Every Rejuvatide lot of GHRP-2 is tested by an independent laboratory for purity by HPLC and identity by mass spectrometry, and is also tested for endotoxin. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.
For comparison studies, see the related secretagogues GHRP-6 and ipamorelin, or browse all growth-axis research peptides.
Storage of lyophilized material
GHRP-2 ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.